AptarGroup, Inc
At today's price, AptarGroup, Inc (ATR) is priced for +5.9% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• AptarGroup makes the dispensing devices that deliver products, from the nasal sprays and injectable components that put drugs into patients to the pumps and closures on beauty and beverage packaging, and its Pharma segment is the crown jewel at 46% of revenue with the highest margins and the most defensible position. • The defining near-term risk is that growth is currently uneven: reported first-quarter sales rose 11% but organic demand was roughly flat, with a destocking headwind in emergenc
Is ATR overvalued? See what's priced in →
525 institutional managers reported holding ATR in 13F filings for the quarter ended 2026-03-31. Together they hold about 93% of the company; the top 10 hold 50%. 78 opened new positions that quarter. Held by Vanguard Group, BlackRock, Morgan Stanley, among others. On the short side, 2.3M shares were sold short as of the 2026-06-15 count, about 4% of shares outstanding (5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ATR has cut its share count 2.7% over the past five years, spending $751.44M on repurchases. It pays a dividend, and has paid one every year in our records (17 and counting), raised 16 years straight; the current rate is $1.83 a share annually. Cash returned over the past three years: $319.66M in dividends and $552.13M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at ATR over the trailing three years. Absence is a fact about the company, not a signal. 20 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ATR's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-29 | +3.2% | +1.0% |
| 2023-10-27 | +0.1% | +2.0% |
| 2024-02-10 | +5.4% | -1.3% |
| 2024-04-27 | +2.4% | -1.8% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ATR's latest 8-K filings: 2026-05-13 (items 5.02); 2026-05-07 (items 5.07); 2026-04-30 (items 2.02, 9.01); 2026-03-17 (items 5.02, 9.01); 2026-02-05 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.